Founded September 2017
Stage Technology development
Investors The Trendlines Group, MOR Research
CEO Asi Cohen-Dotan, PhD
BiPS Medical is developing an innovative wearable, wireless device to monitor vital parameters, including blood pressure, blood oxygen saturation (SpO2), respiration rate, and heart rate.
Designed to replace current manual monitoring performed by nurses every eight hours, the automated monitoring device developed by BiPS will improve patient safety by providing reliable continuous, real-time monitoring of vital indicators. These on-demand measurements will give early warning signals of patient deterioration.
The lightweight device is worn on the fingers and regularly analyzes the information obtained from multiple sensors simultaneously.
National phase (United States, Europe, Israel, China, Japan)
Watch the BiPS Medical animation.
Experienced executive with more than 10 years of scientific, technical, and management experience in the biotech industry; PhD, neurophysiology, Ben-Gurion University of the Negev
Director, Intensive Care Department Tel Aviv Sourasky Medical Center; extensive experience in civilian and battlefield trauma, air evacuation of severely injured casualties, and disaster medicine
ENT surgeon, Kaplan Medical Center; MD, BSc, electronic engineering, Tel Aviv University
Data scientist; PhD, computational neuroscience, BSc, physics and biology, Tel Aviv University
Biomedical engineer with deep domain expertise in digital signal processing; research experience in sensory-motor integration of kinesthetic and tactile information
Current bedside monitoring of many hospitalized patients in general care wards is often limited to spot checks by nurses about every eight hours. Checks includes physiologic parameters such as heart rate, blood pressure, respiratory rate, and temperature. Unfortunately, this leaves patients unmonitored the majority of time, and may lead to clinical deterioration of the patient’s condition.
According to an article in the January 2016 Journal of Clinical Nursing (Watkins T, Whisman L, Booker P.), patient deterioration is often preceded by changes in vital signs; and therefore, continuous vital sign surveillance can enhance patient safety.
Current wearable vital sign monitoring devices have numerous drawbacks: cumbersome, lack ability to measure blood pressure, require multiple devices, and may not be accurate enough.
With an estimated 900,000 beds in U.S. hospitals, the company estimates the U.S. market potential at approximately $720 million, with global potential reaching $1.6 billion.